137 related articles for article (PubMed ID: 9849494)
1. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
Wymenga AN; de Vries EG; Leijsma MK; Kema IP; Kleibeuker JH
Eur J Cancer; 1998 Jul; 34(8):1293-4. PubMed ID: 9849494
[TBL] [Abstract][Full Text] [Related]
2. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
[TBL] [Abstract][Full Text] [Related]
3. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Dizdar V; Gilja OH; Hausken T
Neurogastroenterol Motil; 2007 Dec; 19(12):977-82. PubMed ID: 17973637
[TBL] [Abstract][Full Text] [Related]
4. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome.
Nielsen OH; Hvid-Jacobsen K; Lund P; Langholz E
Digestion; 1990; 46(2):89-96. PubMed ID: 2147664
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Wilde MI; Markham A
Drugs; 1996 Nov; 52(5):773-94. PubMed ID: 9118822
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron in carcinoid syndrome.
Platt AJ; Heddle RM; Rake MO; Smedley H
Lancet; 1992 Jun; 339(8806):1416. PubMed ID: 1375972
[No Abstract] [Full Text] [Related]
7. Effect of the 5-HT3 receptor antagonist, ondansetron, on gastric size in dyspeptic patients with impaired gastric accommodation.
Marzio L; Cappello G; Grossi L; Manzoli L
Dig Liver Dis; 2008 Mar; 40(3):188-93. PubMed ID: 18242155
[TBL] [Abstract][Full Text] [Related]
8. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.
Schwörer H; Münke H; Stöckmann F; Ramadori G
Am J Gastroenterol; 1995 Apr; 90(4):645-8. PubMed ID: 7717328
[TBL] [Abstract][Full Text] [Related]
9. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.
von der Ohe MR; Camilleri M; Kvols LK
Gastroenterology; 1994 May; 106(5):1184-9. PubMed ID: 8174881
[TBL] [Abstract][Full Text] [Related]
10. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
11. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
12. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
13. The effect of ondansetron on gastric emptying in the conscious rat.
Forster ER; Dockray GJ
Eur J Pharmacol; 1990 Nov; 191(2):235-8. PubMed ID: 2150819
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases.
Zimmer C; Kienbaum P; Wiesemes R; Peters J
Anesthesiology; 2003 Apr; 98(4):1007-11. PubMed ID: 12657865
[No Abstract] [Full Text] [Related]
15. Prophylactic administration of ondansetron in emergency intraabdominal operations.
Ulusoy HO; Aktürk G; Lüleci N; Kalaç N; Albayrak D
Middle East J Anaesthesiol; 1996 Jun; 13(5):513-26. PubMed ID: 8994179
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
Reid K; Palmer JL; Wright RJ; Clemes SA; Troakes C; Somal HS; House F; Stott JR
Br J Clin Pharmacol; 2000 Jul; 50(1):61-4. PubMed ID: 10886120
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
Gregor M
Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
[TBL] [Abstract][Full Text] [Related]
20. [Ondansetron in carcinoid syndrome].
Buhl C; Fibbe C; Frenzel H
Dtsch Med Wochenschr; 1992 Nov; 117(47):1821. PubMed ID: 1425313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
